

anti-inflammatoxy and immuno-therapy - all results

Treatment	Number of studies	clinical deterioration	clinical improvement	deaths	viral clearance
Immunostimulants drugs	21 studies ¹	0.24 [0.10 ; 0.56], 1 RCT, I2=0% certainty unassessable	-	0.39 [0.14 ; 1.08], 9 RCTs, I2=22% inconclusive result	1.08 [0.45 ; 2.60], 2 RCTs, I2=72% inconclusive result
anti-inflammatory therapies	2 studies ²	-	-	0.55 [0.19 ; 1.54], 2 RCTs, I2=0% inconclusive result	-
corticosteroids	2 studies ³	-	-	0.98 [0.06 ; 15.76], 2 RCTs, I2=0% inconclusive result	-
inhaled corticosteroids	2 studies ⁴	0.16 [0.03 ; 0.74], 1 RCT, I2=0% demonstrated certainty unassessable	1.21 [1.08 ; 1.36], 2 RCTs, I2=0% demonstrated moderate degree of certainty	-	-

Notes

¹ACTIV-2 SNG001, 2022 (NCT04518410); CoV-Early (Gharbharan), 2022 (NCT04589949); TOGETHER interferon lambda, 2022 (NCT04727424); BLAZE-1 phase 3 (combo), 2021 (NCT04427501); COMET-ICE, 2021 (NCT04545060); CONV-ERT, 2021 (NCT04621123); Cov-2069 (Cohort B : positive SARS-CoV-2 RT-qPCR test result), 2021 (NCT04452318); CT-P59 3.2 part 1, 2021 (NCT04602000); CT-P59 3.2 part 2, 2021 (NCT04602000); Feld, 2021 (NCT04354259); OPTIMISE-C19 (bamlanivimab-etesevimab vs casirivimab-imdevimab), 2021 (NCT04790786); BLAZE-1 phase 2 (combination with etesevimab), 2020 (NCT04427501); BLAZE-1 phase 2 (monotherapy), 2020 (NCT04427501); C3PO, 2020 (NCT04355767); Cov-2067 Weinreich (1200mg) Cohort 1, 2020 (NCT04425629); ACTIV-2 (BRIL-196 and BRIL-198), 0 (NCT04518410); BLAZE 4 LY-CoV1404, 0 (NCT04634409); BLAZE-4, 0 (NCT04634409); TACKLE, 0 (NCT04723394); Bariola, 2021 ()

²COLCORONA, 2021 (NCT04322682); PRINCIPLE (COLCHICINE), 2021 (ISRCTN86534580)

³Clemency, 2021 (NCT04377711); Ezer N (CONTAIN), 2021 (NCT04435795)

⁴PRINCIPLE, 2021 (ISRCTN86534580); STOIC, 2021 (NCT04416399)